Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue (EB) Targeted Radiotherapeutic (EB-TRT)

Audio By Carbonatix

WEST CHESTER, Pa.--(BUSINESS WIRE)--Oct 10, 2025--

Molecular Targeting Technologies, Inc. (MTTI) has filed a formal legal complaint in the Court of Common Pleas for Chester County, Pennsylvania concerning the unauthorized use of its EB-TRT technology by Dr. Xiaoyuan (Shawn) Chen, a former consultant who had previously worked with the company in a professional capacity pursuant to a consulting services agreement.

During his engagement with MTTI, Dr. Chen was granted access to proprietary EB-TRT technology under strict confidentiality. MTTI subsequently discovered that Dr. Chen committed multiple breaches of his consulting services agreement by, among other things, co-founding a new enterprise, which is utilizing key aspects of MTTI’s protected intellectual property without authorization or license to start the company.

“MTTI has always been committed to innovation and the lawful protection of our intellectual property. MTTI obtained the commercial license of this technology from National Institutes of Health of United States of America,” said Dr. Chris Pak, President & CEO at MTTI. “We view this matter with the utmost seriousness and have taken appropriate legal steps to safeguard our technology and the interests of our stakeholders.”

The legal complaint alleges that Dr. Chen acted in direct violation of multiple contractual obligations arising from his prior role as a consultant for MTTI. In addition to this filing, MTTI is conducting broader investigation and considering legal actions in other jurisdictions.

At this time, MTTI will not be commenting further while legal proceedings are underway.

Molecular Targeting Technologies, Inc. (MTTI). MTTI is a clinical stage biotech company developing the Albumin-Binding Evans blue (EB) targeted radiotherapeutic (EB-TRT). MTTI is committed to building value by translating innovative EB-TRT to improve human healthcare. For more information:www.mtarget.com. Contact: Chris Pak, Email: [email protected].

View source version on businesswire.com:https://www.businesswire.com/news/home/20251013226693/en/

Chris Pak, Email: [email protected]

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH LEGAL OTHER SCIENCE GENERAL HEALTH RESEARCH SCIENCE

SOURCE: Molecular Targeting Technologies, Inc.

Copyright Business Wire 2025.

PUB: 10/10/2025 07:27 PM/DISC: 10/10/2025 07:26 PM

http://www.businesswire.com/news/home/20251013226693/en